IFNB1 and myeloid sarcoma: From 2757 MS patients recruited in Sweden and Germany and treated with three different IFNβ preparations (Table 1), bADA levels were measured by capture ELISA [20] and nADA titers using a luciferase-based bioassay [21, 22] (Additional files 1-3).